Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976918 | 0.97 | CYP3A4 (0.48) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL2007741 | 0.93 | OPRM1 (0.45) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL19410760 | 0.92 | CYP3A4 (0.44) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL1684100 | 0.88 | OPRM1 (0.48) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL7733840 | 0.88 | CYP3A4 (0.63) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL1311224 | 0.87 | CYP3A4 (0.52) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL1282252 | 0.87 | OPRM1 (0.47) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| Tert-Butyl Formate SCHEMBL27609525 | 0.87 | CYP3A4 (0.41) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL23225659 | 0.86 | CYP3A4 (0.66) | CYP3A4ABCB11LMNACYP1A2CHRM2 | |
| SCHEMBL20103745 | 0.86 | CYP3A4 (0.61) | CYP3A4ABCB11LMNACYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228364-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | Novartis AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | MEINGASSNER JOSEF GOTTFRIED | 2009-09-10 | — | — | US | disclosed |
| CN-100509774-C | Acylsulfonamide compounds as steroid sulfatase inhibitors | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| US-7482462-B2 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| CN-101137374-A | Combination of a steroid sulfatase inhibitor and an ascomycin | NOVARTIS AG (CH) | 2008-03-05 | — | — | CN | disclosed |
| CN-101137375-A | Anti-inflammatory compounds | NOVARTIS AG (CH) | 2008-03-05 | — | — | CN | disclosed |
| EP-1861098-A1 | ANTI-INFLAMMATORY COMPOUNDS | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861099-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097293-A2 | COMBINATION OF A STEROID SULFATASE INHIBITOR AND AN ASCOMYCIN | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097292-A1 | ANTI-INFLAMMATORY COMPOUNDS | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20050059712-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | disclosed |
| CN-1564811-A | Acylsulfonamides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2005-01-12 | — | — | CN | disclosed |
| EP-1436253-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | Novartis AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003031397-A1 | ACYLSULFONAMIDES AS INHIBITORS OF STEROID SULFATASE | NOVARTIS AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293758-A1 | Combination of a Steroid Sulfatase Inhibitor and an Ascomycin | STS, ARSA, CYP17A1 | CYP3A4 1118/4885ABCB11 517/4885LMNA 4393/4885 |
| US-20090227620-A1 | ANTI-INFLAMMATORY COMPOUNDS | STS, SERPINB1, MPO | CYP3A4 450/4885ABCB11 1380/4885LMNA 4383/4885 |
| US-20050059712-A1 | Acylsulfonamides as inhibitors of steroid sulfatase | STS, SULT2A1, ARSA | CYP3A4 347/4885ABCB11 830/4885LMNA 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.